In the third decade of the 21st century, a gemcitabine-conjugated anti-glypican-3 (GPC3) aptamer has been developed for targeting hepatocellular carcinoma (HCC) cell lines and xenograft models (Park et al., 2020). Here, GPC3 is linked to hepatocellular carcinoma.